Sutcliffe A, Kaur D, Page S, Woodman L, Armour C L, Baraket M, Bradding P, Hughes J M, Brightling C E
Institute for Lung Health, Department of Infection, University of Leicester, Leicester, UK.
Thorax. 2006 Aug;61(8):657-62. doi: 10.1136/thx.2005.056770. Epub 2006 Apr 6.
Mast cell microlocalisation within the airway smooth muscle (ASM) bundle is an important determinant of the asthmatic phenotype. We hypothesised that mast cells migrate towards ASM in response to ASM derived chemokines.
Primary ASM cultures from subjects with and without asthma were stimulated with interleukin (IL)-1beta, IL-4, and IL-13 alone and in combination. Mast cell chemotaxis towards these ASM supernatants was investigated, and the chemotaxins mediating migration by using specific blocking antibodies for stem cell factor (SCF) and the chemokine receptors CCR3, CXCR1, 3 and 4 as well as the Gi inhibitor pertussis toxin and the tyrosine kinase inhibitor genistein were defined. The concentrations of CCL11, CXCL8, CXCL10, TGF-beta, and SCF in the supernatants were measured and the effect of non-asthmatic ASM supernatants on the mast cell chemotactic activity of asthmatic ASM was examined.
Human lung mast cells and HMC-1 cells migrated towards Th2 stimulated ASM from asthmatics but not non-asthmatics. Mast cell migration was mediated through the combined activation of CCR3 and CXCR1. CCL11 and CXCL8 expression by ASM increased markedly after stimulation, but was similar in those with and without asthma. ASM supernatants from non-asthmatics inhibited mast cell migration towards the asthmatic ASM supernatant.
Th2 stimulated ASM from asthmatics is chemotactic for mast cells. Non-asthmatic ASM releases a mediator or mediators that inhibit mast cell migration towards stimulated asthmatic ASM. Specifically targeting mast cell migration into the ASM bundle may provide a novel treatment for asthma.
气道平滑肌(ASM)束内肥大细胞的微定位是哮喘表型的一个重要决定因素。我们假设肥大细胞会响应ASM衍生的趋化因子而向ASM迁移。
分别单独及联合用白细胞介素(IL)-1β、IL-4和IL-13刺激来自哮喘患者和非哮喘患者的原代ASM培养物。研究肥大细胞对这些ASM上清液的趋化作用,并通过使用针对干细胞因子(SCF)、趋化因子受体CCR3、CXCR1、3和4的特异性阻断抗体以及Gi抑制剂百日咳毒素和酪氨酸激酶抑制剂染料木黄酮来确定介导迁移的趋化因子。测量上清液中CCL11、CXCL8、CXCL10、转化生长因子-β(TGF-β)和SCF的浓度,并检测非哮喘患者的ASM上清液对哮喘患者ASM的肥大细胞趋化活性的影响。
人肺肥大细胞和HMC-1细胞向哮喘患者经Th2刺激的ASM迁移,但不向非哮喘患者的ASM迁移。肥大细胞迁移是通过CCR3和CXCR1的联合激活介导的。刺激后ASM中CCL11和CXCL8的表达显著增加,但在哮喘患者和非哮喘患者中相似。非哮喘患者的ASM上清液抑制肥大细胞向哮喘患者的ASM上清液迁移。
哮喘患者经Th2刺激的ASM对肥大细胞具有趋化作用。非哮喘患者的ASM释放一种或多种介质,抑制肥大细胞向受刺激的哮喘患者ASM迁移。特异性靶向肥大细胞向ASM束内的迁移可能为哮喘提供一种新的治疗方法。